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Background: Bypass Angioplasty Revascularization Investigation in type-2 Diabetes (BARI2D) reported similar outcomes for medical therapy (Med) 
and revascularization (Revasc) strategy in diabetic patients (pts) with coronary disease (CAD). Since Drug eluting stents (DES) were available midway 
through BARI2D, we compared outcomes stratified by DES vs. Bare Metal Stent (BMS) use.
Methods: Overall, 807 pts were randomized to Med, 798 to Revasc (260 DES, 424 BMS,114 excluded for no stent / Revasc after time window). 
Kaplan-Meier survival analyses was used to compare four-year clinical events and Chi-square test for self-reported angina.
Results: Baseline characteristics of Med and Revasc pts were well matched. Med, BMS and DES pts had similar four-year rates of death, MI, 
stroke, whereas self-reported angina, equal at baseline, was less in DES and BMS pts over first two years (Table). In subgroup analysis, Death/MI/
Stroke rates were similar in DES vs.BMS vs.Med pts with one vessel (19% vs.17% vs.18%,P=0.99), multivessel disease (23% vs.26% vs.24%,P=0.64), 
myocardial jeopardy <50% (20% vs.21% vs.19%,P=0.92) and >=50% (23% vs.26% vs.27%,P=0.84). At four years, 43% of Med Rx, 32% of BMS and 
24% of DES pts required revasc (P<0.0001 for all; P=0.95 for BMS vs.DES).
Conclusions: In BARI2D, a strategy of routine Revasc in diabetic pts with CAD did not improve four year outcomes compared to Med, regardless of 
stent type. However, DES pts reported less angina at two years, a benefit that was not maintained at four years.
Table: Four-Year Rate of Clinical Events within PCI Stratum of BARI2D
Outcome Med Rx (N=807) DES (N=260) BMS (N=424) P Value
Death,% 7 8.2 8.8 0.51
MI,% 10.1 8.6 12 0.38
Stroke,% 2.7 2.3 2.6 0.90
Death/MI/Stroke 16.1 17.8 20.5 0.13
Baseline Angina,% 59 60 61 0.92
1-year Angina,% 58 45 49 <0.001
2-year Angina,% 40 28 26 0.005
3-year Angina,% 35 27 33 0.13
4-year Angina,% 29 24 26 0.35
